Motokazu Sugimoto1, Michael B Farnell1, David M Nagorney1, Michael L Kendrick1, Mark J Truty1, Rory L Smoot1, Suresh T Chari2, Michael R Moynagh3, Gloria M Petersen4, Rickey E Carter4, Naoki Takahashi5. 1. Department of Surgery, Division of Subspecialty General Surgery, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA. 2. Department of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA. 3. Department of Radiology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA. 4. Department of Health Sciences Research, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA. 5. Department of Radiology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA. takahashi.naoki@mayo.edu.
Abstract
BACKGROUND: The aim of this study was to investigate the impact of decreased skeletal muscle (SM) volume on survival outcomes in patients undergoing surgical resection for pancreatic ductal adenocarcinoma (PDAC). METHODS: Between March 2000 and February 2015, 323 patients who underwent upfront surgical resection for PDAC were identified from the Mayo Clinic SPORE in Pancreatic Cancer. Body composition data, including SM area, subcutaneous adipose tissue area, and visceral adipose tissue area were calculated using an abdominal computed tomography (CT) image at the third lumbar spinal level. The body composition data were normalized by patients' height (e.g., SM index, cm2/m2) and analyzed as continuous variables. Clinicopathological findings and body composition data at initial diagnosis were evaluated for association with overall survival and recurrence-free survival. RESULTS: Because the median SM index was significantly different between males vs. females (49.9 cm2/m2 [range, 32.0-70.3] vs. 39.4 cm2/m2 [range, 29.2-66.2], P < 0.001), it was standardized for each sex and used for further analyses. Parameters independently associated with a shorter overall survival were a larger tumor size (P = 0.007), a greater tumor extent (P = 0.037), a higher carbohydrate antigen 19-9 level (P < 0.001), and a smaller sex-standardized SM index (P = 0.011). Parameters independently associated with a shorter recurrence-free survival were female sex (P = 0.029), a larger tumor size (P < 0.001), a higher carbohydrate antigen 19-9 level (P = 0.001), and a smaller sex-standardized SM index (P = 0.007). CONCLUSIONS: A smaller sex-standardized SM index is a predictive factor for shorter overall and recurrence-free survival in PDAC patients undergoing surgery.
BACKGROUND: The aim of this study was to investigate the impact of decreased skeletal muscle (SM) volume on survival outcomes in patients undergoing surgical resection for pancreatic ductal adenocarcinoma (PDAC). METHODS: Between March 2000 and February 2015, 323 patients who underwent upfront surgical resection for PDAC were identified from the Mayo Clinic SPORE in Pancreatic Cancer. Body composition data, including SM area, subcutaneous adipose tissue area, and visceral adipose tissue area were calculated using an abdominal computed tomography (CT) image at the third lumbar spinal level. The body composition data were normalized by patients' height (e.g., SM index, cm2/m2) and analyzed as continuous variables. Clinicopathological findings and body composition data at initial diagnosis were evaluated for association with overall survival and recurrence-free survival. RESULTS: Because the median SM index was significantly different between males vs. females (49.9 cm2/m2 [range, 32.0-70.3] vs. 39.4 cm2/m2 [range, 29.2-66.2], P < 0.001), it was standardized for each sex and used for further analyses. Parameters independently associated with a shorter overall survival were a larger tumor size (P = 0.007), a greater tumor extent (P = 0.037), a higher carbohydrate antigen 19-9 level (P < 0.001), and a smaller sex-standardized SM index (P = 0.011). Parameters independently associated with a shorter recurrence-free survival were female sex (P = 0.029), a larger tumor size (P < 0.001), a higher carbohydrate antigen 19-9 level (P = 0.001), and a smaller sex-standardized SM index (P = 0.007). CONCLUSIONS: A smaller sex-standardized SM index is a predictive factor for shorter overall and recurrence-free survival in PDACpatients undergoing surgery.
Authors: Jeannine Bachmann; Mathias Heiligensetzer; Holger Krakowski-Roosen; Markus W Büchler; Helmut Friess; Marc E Martignoni Journal: J Gastrointest Surg Date: 2008-03-18 Impact factor: 3.452
Authors: Stefan Buettner; Doris Wagner; Yuhree Kim; Georgios A Margonis; Martin A Makary; Ana Wilson; Kazunari Sasaki; Neda Amini; Faiz Gani; Timothy M Pawlik Journal: J Am Coll Surg Date: 2015-12-23 Impact factor: 6.113
Authors: Matthias Kraft; Kathleen Kraft; Simone Gärtner; Julia Mayerle; Peter Simon; Eckhard Weber; Kerstin Schütte; Jens Stieler; Heide Koula-Jenik; Peter Holzhauer; Uwe Gröber; Georg Engel; Cornelia Müller; You-Shan Feng; Ali Aghdassi; Claudia Nitsche; Peter Malfertheiner; Maciej Patrzyk; Thomas Kohlmann; Markus M Lerch Journal: Nutr J Date: 2012-07-23 Impact factor: 3.271
Authors: David Pj van Dijk; Marcel Cg van de Poll; Alastair Gw Moses; Thomas Preston; Steven Wm Olde Damink; Sander S Rensen; Nicolaas Ep Deutz; Peter B Soeters; James A Ross; Kenneth Ch Fearon; Cornelis Hc Dejong Journal: J Cachexia Sarcopenia Muscle Date: 2015-04-20 Impact factor: 12.910
Authors: Nicolas Linder; Alexander Schaudinn; Katharina Langenhan; Felix Krenzien; Hans-Michael Hau; Christian Benzing; Georgi Atanasov; Moritz Schmelzle; Thomas Kahn; Harald Busse; Michael Bartels; Ulf Neumann; Georg Wiltberger Journal: BMC Med Imaging Date: 2019-04-27 Impact factor: 1.930
Authors: Josh McGovern; Ross D Dolan; Paul G Horgan; Barry J Laird; Donald C McMillan Journal: J Cachexia Sarcopenia Muscle Date: 2021-10-18 Impact factor: 12.910